Press release
Malmö, November 6, 2017
Acarix AB to seek new CEO
Acarix AB (publ) ("Acarix") announced today that CEO Søren Rysholt Christiansen has resigned on 6 Nov. 2017, with the effect to leave the company at the end of February 2018 latest. The Board has begun a search for Mr. Christiansen's successor.
"The Board is thankful for Søren's leadership in the transition from being a development company to initiate its commercialization" said Dr. Braun, chairman of Acarix. "We are grateful for his efforts that have taken the company to this point in the course of just one year. I am confident that working with our executive leadership team, the Company will enjoy continued success in the future. With our engaged colleagues and leading technology, we are well positioned to meet the growing needs of patients, doctors, and healthcare organizations," said Dr. Braun.
Mr. Christiansen said, "It has been an enormous privilege to help grow Acarix, and lay the first bricks for the commercialization. I am proud to have worked with the employees, consultants and investors who are so committed to advancing our products for the sake of the patients."
The CADScor®System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient-specific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes.
Contacts:
Acarix
Dr. Werner Braun, Chairman, E-mail: [email protected], Phone: +49 151 70 131 343
Søren Rysholt Christiansen, CEO, E-mail: [email protected], Phone: +45 2777 1112
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 14:40 CEST on November 06, 2017.
Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team. The Acarix CADScor®System has been designed to be an all-in-one system to non-invasively measure and display a patient-specific CAD-score to help doctors assess the risk of coronary artery disease. The system has been clinically validated.
See more at www.acarix.com. Press kit: http://www.acarix.com/about-us/press-downloads/.
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire
